<DOC>
	<DOCNO>NCT02548741</DOCNO>
	<brief_summary>This study design investigate effect metformin , commonly prescribe first line medication diabetes recommend prediabetes , level potentially tissue damage reactive product ( MG ) blood clear counterpart urine ( IMZ ) . The study involve patient elevate HbA1c randomize receive either metformin similar inactive placebo pill group sex age match volunteer without diabetes . Study participant recruit University Arizona Medical Center , South Campus clinic ( Endocrine clinic , family medicine clinic general medicine clinic ) . Eighty patient HbA1c &gt; 6.0 % randomize receive either metformin similar inactive placebo 6 week . The response patient compare 40 patient normal HbA1c &lt; 5.6 % receive either study medication . Investigators compare plasma MG urine IMZ concentration/content 3 group 6-week intervention . It hypothesize plasma MG level metformin treatment group less group take placebo pill , significant difference MG level metformin treatment group volunteer without diabetes .</brief_summary>
	<brief_title>Evaluation Metformin Effect Methylglyoxal Patients With Type 2 Diabetes</brief_title>
	<detailed_description>A prospective randomized control clinical trial 120 adult patient conduct June 2015 June 2017 ( 2 year ) . Study participant recruit University Arizona Medical Center , South Campus clinic ( Endocrine clinic , family medicine clinic general medicine clinic ) . Eighty patient HbA1c* &gt; 6.0 % randomize receive either metformin similar inactive placebo 6 week . The response patient compare 40 patient normal HbA1c &lt; 5.6 % receive either study medication . Twenty four-hour urine sample analyze measure metformin-MG adducted product ( IMZ ) baseline ( D0 ) end study period ( D42 ) . Blood sample analyze baseline measure plasma methylglyoxal concentration ( baseline MG concentration- D0 ) re-measure end study period ( D42 ) . Mass spectrometry perform sample analysis detect plasma methylglyoxal ( MG ) level . Metformin-MG adducted product ( IMZ ) measure use Multiple Reaction Method ( MRM ) . Also , Mass spectrometry perform detect plasma protein modification baseline end study period ( 6 week ) . Investigators measure concentration IMZ MG human urine plasma cohort nM μM range , respectively via mass spectrometry . Investigators normalize value specific gravity . A logbook provide participant record blood sugar measurement home . Investigators provide glucometer ( One Touch glucometer ) , strips lancet patient never glucometer enrol study . Participants take metformin placebo ask perform 4-point self-measured blood sugar profile measurement take indicated table ( week ) . Investigators contact study participant ( treatment placebo group ) phone mid study period ( D21 ) follow record fasting blood glucose level development side effect . The result blood sugar measurement help study physician adjust diabetes therapy ( metformin concomitant diabetes medication ) order study subject maintain appropriate blood glucose control ( target pre-meal bedtime glucose 90-180 mg/dL ) . The participant non-diabetic group , receive either metformin hydrochloride placebo . Their fasting blood glucose , plasma MG level urine IMZ level measure study . They require perform 4 point test . They clinic visit lab order diabetic patient except receive study medication . It hypothesize plasma MG level metformin treatment group less group take placebo pill , significant difference MG level metformin treatment group volunteer without diabetes .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Elevated HbA1c &gt; 6.0 % ( patient type 2 diabetes mellitus prediabetes ) , HbA1C &lt; 9.0 % For matched nondiabetic patient : HbA1C ≤ 5.6 % Serum creatinine ( SCr ) &lt; 1.5 mg/dL male &lt; 1.4 mg/dL female , Calculated glomerular filtration rate ( GFR ) &gt; 60 ml/min/1.73m2 , Body mass index ( BMI ) 2540 kg/m2 , Glycosylated hemoglobin A1C ( HA1C ) &lt; 9 % , No know intolerance metformin Has take metformin previous 3 month Patients thiazolidinediones ( TZD ) Patients history metformin intolerance ( gastrointestinal side effect poor renal function ; Serum Cr &gt; 1.5mg/dL male &gt; 1.4 mg/dL female calculate GFR &lt; 60 mL/min/1.73m2 Patients active ( symptomatic unstable ) cardiovascular disease Patients require home oxygen Patients endstage liver disease ( cirrhosis ) Patients oral glucocorticoid within past 30 day ( equivalent prednisone &gt; 5mg/day ) Excessive alcohol intake ( The Substance Abuse Mental Health Services Administration ( SAMHSA ) define heavy drinking drink 5 drink occasion 5 day past 30 day ) 29 Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Metformin</keyword>
	<keyword>diabetes</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>diabetes complication</keyword>
	<keyword>methylglyoxal</keyword>
	<keyword>Prediabetes</keyword>
</DOC>